Quivax University Vaccine Against Covid-19: A Breakthrough in Scientific Development
Press Conference Highlights
At a press conference, authorities from the Autonomous University of Querétaro (UAQ) and researchers from this Institution presented the results regarding the Quivax university vaccine against Covid-19, as well as the advances that have been made in terms of scientific development for this House of Studies.
According to Dr. Teresa García Gasca, rector of the UAQ, this biannual report aims to inform society about the results that this project has had, strengthened with the support of the population and other institutions, which is a reason to continue these investigations.
“We did not stop, it was a project where all the enthusiasm and heart were put into it and I think the results are sensational for what could be done with the resources and conditions with which we work,” said the Rector.
Impressive Vaccine Prototypes
During his presentation, Dr. Juan Joel Mosqueda Gualito, project researcher, expressed that up to now, the Alma Mater from Queretaro has created five vaccine prototypes, two of which have been fully evaluated with cellular, humoral, and neutralization responses against worrying variants. Additionally, two protein vaccine prototypes for intranasal administration have shown demonstrated humoral and cellular effects. Another prototype based on nanoparticles is currently under evaluation. Lastly, a vaccine against Covid-19 developed in collaboration with Dr. Greco Hernández and Dr. Erika Alejandra García Hernández, specialists in RNA molecules, is being developed using messenger RNA molecules.
This research has also generated significant academic contributions, including three theses, three scientific manuscripts, four collaboration agreements, and two postdoctoral fellowships. The project has also been presented in four national and international conferences.
Investment in Vaccine Development
It was announced that the Autonomous University of Querétaro will establish a specialized laboratory for professional vaccine development, making it the second of its kind in the country and the first in Querétaro. Dr. García Gasca reported that the university has invested over 3 million pesos from its own resources, with additional funding from the Mexican Agency for International Development Cooperation (Amexid) and other sources. These funds have been utilized for the acquisition of materials, laboratory equipment, professional fees, and other necessary resources.
Future Auditing and Conclusion
The university authorities emphasized that all the resources allocated to the project will be audited by an external office. A final report will be prepared by November once the auditing process is completed. The team involved in the investigation includes Mr. Luis Alberto Fernández García, Private Secretary, and the scientists in charge: Dr. Diego Josimar Hernández Silva, Dr. Lineth Juliana Vega Rojas, and Mr. Miguel Andrés Velazco Elizondo.
Totypes have been developed and are currently undergoing evaluation. These prototypes have shown promising results in terms of effectiveness and safety.
Dr. Mosqueda Gualito emphasized the interdisciplinary nature of the research, involving experts from various fields such as biology, biochemistry, genetics, and immunology. This collaboration has allowed for a comprehensive approach in developing the vaccine.
Future Steps and Collaboration
Moving forward, the Quivax University team plans to continue evaluating and improving the vaccine prototypes. They aim to optimize the formulations and dosage to ensure maximum efficacy and safety.
The researchers also expressed their gratitude for the support and collaboration they have received from other institutions and the community. They emphasized the importance of teamwork and shared resources in combating the Covid-19 pandemic.
Hope for the Future
The Quivax University vaccine against Covid-19 represents a significant breakthrough in scientific development. The preliminary results and ongoing research indicate great potential for the vaccine to contribute to the global efforts in controlling and eradicating the virus.
The team remains hopeful and dedicated in their pursuit to provide an effective solution to the ongoing pandemic, and they encourage continued support from the public and scientific community.
What are some of the measures that are being taken to optimize the effectiveness and safety of the Quivax University vaccine prototypes?
Some of the measures being taken to optimize the effectiveness and safety of the Quivax University vaccine prototypes include:
1. Preclinical testing: The vaccine prototypes undergo rigorous testing in animal models to assess their safety, efficacy, and immune response stimulation before advancing to human trials.
2. Clinical trials: The vaccine candidates go through three phases of human clinical trials, starting with a small group of volunteers and gradually increasing the number of participants in each subsequent phase. These trials evaluate the vaccine’s safety, effectiveness, and potential side effects.
3. Regulatory approval: Before the vaccine can be released to the public, it must receive regulatory approval from government health agencies such as the Food and Drug Administration (FDA) or the European Medicines Agency (EMA). These agencies review the vaccine’s clinical trial data, manufacturing processes, and safety profiles to ensure its effectiveness and safety.
4. Vaccine surveillance: After the vaccine is approved and distributed, a robust system of vaccine surveillance is established to monitor its safety and effectiveness in real-world conditions. This involves monitoring and reporting any adverse events or side effects to identify any potential safety concerns promptly.
5. Post-marketing studies: Once the vaccine is widely available, post-marketing studies are conducted to assess its long-term safety and effectiveness and monitor rare side effects that may not have been detected during clinical trials.
6. Collaboration and data sharing: Vaccine developers and regulatory authorities collaborate globally to share data, research findings, and safety information of their vaccine candidates. This enables the exchange of knowledge and helps in optimizing the effectiveness and safety of the vaccines.
7. Continuous monitoring and evaluation: Vaccine safety is monitored on an ongoing basis through various systems such as pharmacovigilance programs, adverse event reporting, and risk management strategies. Any emerging safety concerns are promptly investigated and appropriate measures are taken to mitigate any risks.
8. Quality control and manufacturing standards: Strict quality control measures are implemented during vaccine production to ensure consistency, purity, and potency of the vaccine. Good Manufacturing Practices (GMP) are followed to maintain the highest standards of quality and safety.
These measures are essential to optimize the effectiveness and safety of the Quivax University vaccine prototypes and ensure that they provide protection against the target disease while minimizing any potential risks.